Why the Right Provider Changes Everything
A med spa in Texas averaged $40,000 per month in revenue — Botox, fillers, facials. Solid, but flat. Eighteen months later, after adding a structured peptide program, they were at $140,000+ monthly. That case study, documented by Diamond Accelerator, has been cited in nearly every practice expansion conversation happening right now.
The mechanism is straightforward: aesthetic procedures are transactional. Peptide protocols are relational. A patient receiving a monthly GLP-1 or Sermorelin regimen is worth $800–$2,000 per month for 12–24 months. A Botox client is worth $300–$500 every 3–6 months. The math is not subtle.
But here's the problem: the vendor landscape is fragmented, partially opaque on pricing, and inconsistent in what "turnkey" actually means. One company calls itself turnkey while providing protocol PDFs and calling it a day. Another provides everything from a credentialed prescriber network to patient-facing apps.
This guide cuts through it. We've mapped six vendors across the same criteria: what they actually include, what it costs, who they're genuinely best for, and where the real trade-offs live. There is no paid placement here — every section reflects independent research.
The fundamental choice in turnkey peptide setup is speed vs. margin. Platforms that provide prescribers and full infrastructure (Ola Digital Health) get you launched in 2–4 weeks but take 20–30% of revenue. In-house buildouts (Diamond Accelerator) keep 95%+ of margins but require 6–12 weeks and a licensed prescriber on staff.
Quick Comparison Table
For those who need the 30-second version before diving in:
| Provider | Model | Price Range | Best For | In-House Provider Needed? | Launch Time |
|---|---|---|---|---|---|
| Ola Digital Health | White-label telehealth platform | 20–30% revenue share | National scale without hiring | No (included) | 2–4 weeks |
| Diamond Accelerator | Consulting + in-house buildout | $5–15K + $500–2K/mo | Established med spa, in-house prescriber | Yes | 6–12 weeks |
| ShineRX | Protocol subscription | $300–800/month | Practices already prescribing, need structure | Yes | 24–48 hours |
| OptiMantra | EHR + practice management | $500–1,500/month | Building practice infrastructure from scratch | Yes | 1–2 weeks |
| SSRP Institute | Certification/education | $2–5K one-time | Credentialing team before launch | Prereq | 6–12 weeks (course) |
| Brisk Wellness | Affiliate referral | Free to join | Non-licensed wellness professionals | No | Days |
Ola Digital Health
Ola is the closest thing in the peptide space to "Shopify for healthcare." Their platform provides the entire clinical infrastructure — telehealth technology, a pre-credentialed provider network, multi-state DEA registration handling, HIPAA-compliant infrastructure, and pre-built protocol templates — fully white-labeled under your brand. Patients see your practice name throughout. Ola is the backend you never see.
The model excels for practices that want national telehealth reach without the 6–12 month process of hiring, credentialing, and multi-state licensing a prescriber network themselves. It also works for established local med spas that want to add a telehealth revenue stream alongside their in-clinic services.
- Fastest path to multi-state telehealth
- No prescriber hiring or credentialing required
- FDA/DEA compliance handled by platform
- Pre-built protocols reduce launch time
- Full white-label — patients see your brand
- Revenue share cuts significantly into margins
- Provider network quality varies by region
- Limited protocol customization
- Revenue share terms not publicly disclosed
At a 25% platform fee, a $30,000/month peptide revenue stream nets you $22,500. The same revenue through an in-house model (Diamond Accelerator, ~$1K/month fee) nets you $29,000. Over 12 months, that's a $78,000 difference. The question is whether you have the staff and prescriber to make in-house viable.
Diamond Accelerator
Diamond Accelerator takes the consulting approach: they teach your team how to build and run a peptide program in-house, using your own providers and your own infrastructure. Their services include compliance documentation templates, staff training (injectors, front desk, medical assistants), patient education scripts, marketing templates, and business planning with revenue forecasting.
Their most-cited case study: a med spa that grew from $40,000 to $140,000+ in monthly revenue after 3–4 months of working through the program. The mechanism was clear — structured recurring peptide protocols replacing one-time aesthetic transactions, creating a patient LTV that compounds month over month.
The requirement that can't be worked around: you need a licensed prescriber (MD, NP, or PA) on staff. Diamond cannot provide prescribers. If you have that, this model captures significantly more margin than any platform approach.
- No revenue share — keeps 95%+ in-house
- Documented $40K→$140K+ revenue case study
- Customizable to existing practice model
- Comprehensive staff training included
- Compliance documentation ready-to-deploy
- Higher upfront investment ($5–15K)
- Requires in-house licensed prescriber
- 6–12 week implementation timeline
- Needs dedicated staff (medical director + nurses)
ShineRX
ShineRX is the narrowest solution in this comparison: it's a subscription library of pre-built peptide protocol templates, white-label patient education handouts, and compliance documentation. There's no prescriber network, no consulting, and no training beyond the materials themselves. If you already have a licensed prescriber and a working practice, ShineRX gives you infrastructure in under 48 hours.
The product integrates with EHR systems and includes a protocol selection workflow that reduces the decision burden on your medical director. For practices where the bottleneck is standardization — not prescribing authority or compliance — ShineRX solves that at an extremely affordable price point.
- Lowest ongoing cost ($300–800/month)
- 24–48 hour activation for existing practices
- Maintains 95%+ margins
- EHR integration reduces admin burden
- Reduces prescriber decision fatigue
- Doesn't solve prescriber shortage
- No staff training included
- Limited to protocol templates — not a full solution
- Minimal compliance support beyond templates
OptiMantra
OptiMantra is not a peptide-specific platform — it's a cloud EHR built for integrative and aesthetic medicine, with specific templates for peptide practice documentation. If you're building a peptide program from scratch and don't yet have EHR, scheduling, billing, and patient portal infrastructure, OptiMantra solves the entire operational layer in a single platform.
What makes OptiMantra particularly relevant for peptide practices is the built-in membership and subscription management. Recurring peptide protocols are a subscription business model — patients pay monthly, receive monthly shipments or injections, and need portal access, appointment scheduling, and automated billing. OptiMantra's architecture handles this natively, which most general EHRs (Epic, Athena) are not designed for.
- All-in-one: EHR + scheduling + billing + portal
- Built for membership/subscription revenue models
- Transparent, predictable pricing
- Community of integrative practices (peer support)
- Peptide-specific documentation templates included
- Doesn't provide protocols or prescriber network
- Requires some EHR setup literacy
- Smaller integration ecosystem vs. Epic/Cerner
- Ongoing cost adds up without high patient volume
SSRP Institute
SSRP Institute occupies a distinct position in this comparison: it's the only pure education offering. Their 19-lesson certification program trains practitioners (MDs, NPs, PAs, nurses, aestheticians) in clinical peptide therapy — dosing, timing, drug interactions, stacking, patient monitoring, and safety protocols. Instructors include Dr. Paige Haas and other recognized practitioners.
SSRP is not a standalone business solution — it doesn't solve compliance infrastructure, operational management, or patient acquisition. But the certification differentiates a practice in a market increasingly crowded with undercredentialed providers, and provides the clinical confidence that reduces prescribing errors and informed consent gaps.
Think of it as a prerequisite for Diamond Accelerator or an OptiMantra buildout, not a replacement for either. Teams that go through SSRP before a full program launch make fewer compliance mistakes and command higher patient confidence.
- Industry-recognized credential
- Comprehensive clinical training (dosing, stacking, safety)
- Builds patient-facing credibility
- Reduces prescribing errors
- CME credits available
- Education only — doesn't solve operations or infrastructure
- Cost multiplies with team size
- 6–12 week time commitment per person
- Requires healthcare background as prerequisite
Brisk Wellness
Brisk Wellness is the only option in this comparison that requires no clinical license. As an affiliate, you refer clients through a tracked link, Brisk's credentialed provider network handles the clinical relationship, and you earn a commission per qualifying referral. All clinical services, compliance, and prescribing happen on Brisk's side — you're a referral source, not a provider.
The model is cleanest for personal trainers, nutritionists, wellness coaches, and other health-adjacent professionals who have clients asking about peptides but have no prescribing authority. The FTC compliance burden is on the affiliate to disclose the relationship — this is non-negotiable.
Affiliate income from Brisk Wellness is one-time per referral. There is no recurring revenue share. A client you refer who stays on peptides for 24 months and pays Brisk $2,000/month generates $0 ongoing for you after the initial commission. Factor this into any revenue model comparison with the clinical options above.
- No clinical license or compliance burden
- Zero upfront cost
- Quick to launch (days, not weeks)
- FTC-compliant program structure
- One-time commission only — no recurring revenue
- Patient relationship transfers to Brisk entirely
- Competing with many other affiliates
- Revenue ceiling is much lower than clinical models
How to Choose: Decision Framework
The right vendor depends entirely on where your practice sits today — not where you want to be. Here's a four-question framework that narrows the field quickly.
Do you have a licensed prescriber (MD, NP, or PA) on staff?
Yes: You can use any option — and should lean toward Diamond Accelerator, ShineRX, or OptiMantra to maximize margin retention. Platform revenue shares are unnecessary costs when you have in-house prescribing authority.
No: Your realistic options are Ola Digital Health (telehealth platform + their prescriber network) or Brisk Wellness (non-clinical affiliate). Adding a telehealth prescriber partnership via Ola is the only way to offer peptide protocols legally without your own provider.
What is your patient volume and existing practice revenue?
High volume (30+ active patients/month, $50K+ revenue): Diamond Accelerator's investment ($5–15K upfront) pays back quickly against the margin gains from keeping revenue share in-house. The ROI math works clearly.
Low/early-stage (under 20 active patients, building): ShineRX's $300–800/month or OptiMantra's infrastructure makes more sense — lower fixed costs while you build the patient base. Start Ola only if you have an audience but no prescriber.
Do you have operational infrastructure — EHR, scheduling, billing?
No: OptiMantra is the right first step. Building a peptide practice without EHR and subscription billing infrastructure on a general-purpose system (or spreadsheets) creates compliance and operational risks. Solve infrastructure first, add protocols after.
Yes, with existing EHR: ShineRX plugs into most EHR systems in 24–48 hours. If your provider is already prescribing but your team lacks structured protocols, ShineRX is the fastest and most affordable upgrade.
Does your team have clinical training in peptide therapy?
No: Consider SSRP Institute certification as a prerequisite — especially for practitioners who will be actively prescribing and administering. The credential builds patient confidence and reduces prescribing errors. Budget 6–12 weeks and $2–5K per team member.
Yes: Skip the certification cost and direct budget toward infrastructure (OptiMantra) or program buildout (Diamond Accelerator).
For most established med spas with an in-house prescriber: SSRP certification for your medical director → OptiMantra for infrastructure → Diamond Accelerator for program buildout and marketing. This combination gives you clinical credibility, operational foundation, and a proven revenue growth playbook. Timeline: 4–5 months. Expected outcome: $30–60K in new monthly recurring revenue within 12 months.
2026 Compliance Reality Check
Any turnkey vendor evaluation that doesn't address FDA compliance is doing you a disservice. Here is what you need to know going into 2026.
What Changed in 2023–2025
In late 2023, the FDA categorized 17 widely-used peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, and Melanotan II — as "Category 2" bulk drug substances. This means they cannot legally be compounded for human use under FDA 503A rules. Practices or pharmacies still offering these compounds are operating outside FDA guidance and face real enforcement risk.
| Peptide Category | Legal Status (2026) | Notes |
|---|---|---|
| FDA-Approved Branded | ✓ Fully Legal | Ozempic, Wegovy, Zepbound, Mounjaro, etc. Can be prescribed and billed to insurance. |
| Category 1 Compounded | ✓ Legal with Documentation | Sermorelin, NAD+, select others. Can be compounded with documented clinical need. |
| Category 2 Compounded | ✗ Illegal for Human Use | BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604. Cannot be compounded under 503A. Active FDA enforcement. |
| Compounded Semaglutide/Tirzepatide | ⚠ Rapidly Changing | FDA declared shortage ended Dec 2024; compounding now under scrutiny. Consult legal counsel on current status. |
If a vendor's program includes BPC-157, TB-500, or any other Category 2 peptide as core to their protocol offering, ask them directly: how are they addressing FDA 503A compliance? Any vendor that doesn't have a clear, current answer to that question is a liability for your practice, not an asset.
Telemedicine Prescribing Status (2026)
DEA telehealth flexibilities — allowing prescribing of controlled substances without prior in-person evaluation — have been extended through December 31, 2026. Most peptides are not controlled substances, so this primarily affects practices offering mixed programs (peptides + hormone therapy). After December 2026, rules may tighten; plan accordingly if telehealth prescribing is central to your model.
Minimum Compliance Checklist
- Licensed prescriber on staff or credentialed telehealth network (MD/NP/PA licensed in patient's state)
- Valid physician-patient relationship documented with proper evaluation and history
- Compounding pharmacy — state-inspected, 503A-compliant, only compounding legal (Category 1) peptides
- Informed consent — off-label use disclosed, benefits/risks documented, alternatives offered
- Lab monitoring protocol — baseline labs required; monitoring frequency documented per peptide
- HIPAA-compliant infrastructure — all patient data, telehealth platforms, and records
- Marketing compliance — no health claims ("heals tendons," "reverses aging"); only evidence-based descriptions
Building Your Peptide Practice?
Our upcoming pillar guide — How to Add Peptide Services to Your Medical Practice — covers the full implementation roadmap: compliance checklist, hiring timeline, ROI calculator, and pharmacy sourcing guidance.
Browse All Practice Guides →